Personalized medicine: boon or budget-buster?

Area of Science:

• Genomics
• Pharmacology
• Bioethics

Background:

• Personalized medicine aims to tailor treatments based on individual genetic profiles.
• Current understanding of noncoding DNA, drug response interactions, and environmental factors remains limited.
• Epigenetic variations add complexity to developing genetically based medications.

Purpose of the Study:

• To evaluate the potential economic implications of implementing personalized medicine.
• To highlight the significant costs associated with molecular medicine development and profiling.
• To initiate a discussion on the cost-effectiveness of personalized medicine versus traditional approaches.

Main Methods:

• Conceptual analysis of existing knowledge gaps in personalized medicine.
• Economic projection comparing potential costs of molecular medicine with current healthcare models.
• Literature review on genetic factors, drug response, and environmental influences.

Main Results:

• Significant unknowns exist regarding noncoding DNA functions and their impact on drug response.
• The cost of genetic profiling and developing personalized drugs may be substantial.
• Potential costs of molecular medicine could exceed projected savings from improved efficacy.

Conclusions:

• While personalized medicine offers potential benefits, its implementation faces considerable scientific and economic hurdles.
• A thorough economic debate is crucial, especially during the current economic climate, to assess the viability of molecular medicine.
• The
• one drug fits all
• approach, despite its inefficiencies, may remain economically favorable in the short term due to the high costs of personalized medicine.